Rhinoconjunctivitis Quality Of Life Questionnaire Research Articles

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Clinical Trial to Assess the Efficacy and Safety of Yuping Tongqiao Tablets in the Treatment of Persistent Allergic Rhinitis.

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Clinical Trial to Assess the Efficacy and Safety of Yuping Tongqiao Tablets in the Treatment of Persistent Allergic Rhinitis.

Exploring the efficacy and safety of Yu-Ping-Feng powder with variation against allergic rhinitis: a randomized, double-blind, placebo-controlled trial

BackgroundAllergic rhinitis (AR) is a common allergic condition characterized by frequent sneezing, nasal congestion, nasal itching and rhinorrhea. Chinese medicine formula Yu-Ping-Feng Powder with Variation (YPV) is an empirical formula modified from an ancient Chinese medicine formula named Yu-Ping-Feng Powder, which is widely used for the treatment of allergic diseases such as AR and asthma. PurposeTo evaluate the efficacy and safety of YPV on AR patients with the lung and spleen Qi deficiency type using a randomized, double-blind, placebo-controlled clinical trial (RCT).Study design and methodsBetween April 2022 and June 2023, a total of 58 participants were recruited and randomly allocated to receive either YPV (n = 29) or placebo (n = 29) for 8 consecutive weeks. The changes of the Total Nasal Symptom Score (TNSS), and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) or the Paediatric Allergic Disease Quality of Life Questionnaire (PADQLQ) scores at week 8 were used as the primary outcomes. The secondary outcomes included (1) the change of TNSS at weeks 4, 12 and 16; (2) the RQLQ or the PADQLQ scores at weeks 4, 12 and 16; (3) the change of frequency of AR episodes and their severity Visual Analog Scale (VAS) at weeks 4, 8, 12 and 16; (4) the changes of the gut microbiota composition in stool samples at week 8; and (5) adverse events related to the study treatment. ResultsYPV treatment could significantly improve the RQLQ score in AR patients at weeks 4, 8, 12, and 16 (p = 0.05, p = 0.04, p = 0.04 and p = 0.03, respectively), when compared with the placebo treatment. However, it did not improve the TNSS score at week 8 in AR patients when compared with the placebo group. In addition, YPV treatment could reduce the VAS score in AR patients at weeks 12 and 16 when compared with the placebo group, although the reductions were not statistically significant (p = 0.06 and p = 0.08, respectively). Importantly, no overt adverse effects were observed in both YPV and placebo groups.ConclusionYPV was well-tolerated and could effectively ameliorate multiple symptoms of AR and improve the quality of life of AR patients after 8-week treatment.Trial registrationClinicalTrials.gov, NCT04976023. Registered 26 July 2021, https://clinicaltrials.gov/study/NCT04976023?cond=The%20Effects%20of%20Using%20Yupingfeng%20Powder%20with%20Variation%20for%20the%20Treatment%20of%20Allergic%20Rhinitis&rank=2

Posterior Nasal Neurectomy for Eosinophilic Chronic Rhinosinusitis With Allergic Rhinitis: Efficacy Study.

To evaluate the efficacy of posterior nasal neurectomy (PNN) in patients with eosinophilic chronic rhinosinusitis (eCRS) and moderate to severe persistent allergic rhinitis (AR). A total of 42 patients with eCRS and AR were recruited from the Otorhinolaryngology Department of Qingdao University Affiliated Hospital between December 1, 2022, and January 1, 2024. All patients underwent functional endoscopic sinus surgery (FESS), with 20 receiving additional PNN (intervention group) and 22 undergoing FESS alone (control group). Subjective symptoms were assessed using the visual analog scale (VAS), sino-nasal outcome test-22 (SNOT-22), and rhinoconjunctivitis quality of life questionnaire (RQLQ). Objective assessments included the modified Lund-Kennedy endoscopic score and Lund-Mackay CT score. Postoperative nasal secretions were collected for cytokine analysis using enzyme-linked immunosorbent assay (ELISA). Preoperatively, the intervention group exhibited higher rates of excessive sneezing and emotional impact on RQLQ scores (p < 0.05). At 6-month follow-up, the intervention group showed significantly reduced subjective symptom scores (SNOT-22, p = 0.003; RQLQ activity, p < 0.001; nasal symptoms, p = 0.003; eye symptoms, p = 0.002; total RQLQ score, p = 0.007) and improved objective symptoms (Lund-Kennedy score, p < 0.001) compared to the control group. Greater reductions (Δ) were observed in eye symptoms (p = 0.002), emotional (p = 0.002), and Modified Lund-Kennedy score (p < 0.001). Postoperative IL-5 concentrations were lower in the intervention group (p = 0.023). Concurrent PNN with FESS is both safe and effective, leading to significant improvements in both subjective and objective symptoms in eCRS patients with AR. Cytokine analysis further supports the therapeutic benefits of this combined approach.

A clinical study on the combination of bencycloquidium bromide and montelukast in the treatment of moderate to severe allergic rhinitis.

Bencycloquidium bromide (BCQB) is a novel synthesized quaternary ammonium salt compound based on the classic anticholinergic drug ipratropium bromide. This study was to compare the efficacy of BCQB and montelukast (MNT) combination therapy to that of MNT monotherapy in the treatment of moderate to severe allergic rhinitis ((M/S)AR). This study enrolled enrolled 300 patients with (M/S)AR. The participants were randomized to receive BCQB (180 μg each time, qid) plus MNT (10 mg qn) (BCQB + MNT group) or MNT alone (10 mg qn) for 4 weeks. The visual analog scale (VAS) for rhinorrhea, sneezing, nasal congestion, itching, and the rhinoconjunctivitis quality of life questionnaire (RQLQ) were assessed before and at the end of treatments. Adverse events were recorded in detail. FAS analysis was performed on a total of 133 and 134 patients, in the BCQB + MNT group and in MNT group, respectively. The baseline information was comparable. Both treatments significantly reduced the score of total VAS and 4 main VAS symptoms compared to baseline. However, the BCQB + MNT group exhibited significantly greater decrease in scores for rhinorrhea and nasal congestion compared to MNT alone. After 2 weeks of treatment, the BCQB + MNT group showed significantly larger decrease in the RQLQ score in terms of daily living, nonnasal and ocular symptoms, behavioral problems, nasal symptoms, and ocular symptoms compared to MNT alone. At the end of the trial, both treatments significantly reduced the total RQLQ score from baseline; however, the BCQB + MNT group showed significant decrease in scores compared to MNT alone. Mild and transient adverse events were recorded, which were similar between the 2 groups. The combination of BCQB and MNT had a greater overall effect, compared to MNT monotherapy in improving nasal symptoms such as nasal congestion and rhinorrhea, as well as quality of life in the treatment of (M/S)AR.

Feasibility of MASK-air® use in allergic rhinitis patients receiving immunotherapy and the effect on quality of life.

The aim of MASK-air® application is to enhance awareness of allergic rhinitis (AR) and its complications, thereby reducing the risk of developing asthma. The aims of this study were to evaluate the impact of MASK-air® on the quality of life (QoL) and symptomatology of AR patients undergoing allergen immunotherapy (AIT). The study also evaluated patient satisfaction with the application. A prospective cross-sectional study was conducted between August and November 2019 at a tertiary Allergy and Immunology center involving patients receiving AIT. Participants were instructed on accessing and utilizing MASK-air® daily through face-to-face interviews. Concurrently, the Score for Allergic Rhinitis (SFAR) and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) were administered alongside MASK-air® Visual Analog Scale (VAS) scores. After 6 months, RQLQ scores were reassessed and a satisfaction survey was conducted. This study comprised 96 patients. Significant correlations were observed among SFAR, RQLQ, and VAS scores. After 6 months of MASK-air® usage, improvements in QoL and symptom reduction were evident. Notably, participants who consistently used MASK-air® demonstrated significant reductions in activity limitations and hay fever scores compared to irregular users (p = 0.05 and p = 0.02, respectively). Additionally, participants under 40 years of age and those with higher education levels exhibited a greater inclination toward online monitoring via the application. Overall, participants found MASK-air® practical, citing various advantages and disadvantages. MASK-air® serves as a valuable tool for physicians in managing treatment and is associated with validated, reliable scales. Its use was linked to enhanced QoL and symptom reduction among participants, irrespective of treatment duration.

A one‐year efficacy assessment of subcutaneous immunotherapy in dust mite allergic rhinitis patients based on clinical symptoms and objective biomarkers

Abstract ObjectiveTo evaluate the 1‐year efficacy of subcutaneous immunotherapy (SCIT) in treating dust mite‐induced allergic rhinitis (AR) and establish objective biomarkers for efficacy monitoring.MethodsFifty‐nine AR patients underwent 1‐year SCIT. Subjective symptoms were assessed via total nasal symptom score (TNSS), combined symptom/medication score (CSMS), and mini rhinoconjunctivitis quality of life questionnaire (MiniRQLQ). Serum total immunoglobulin E (tIgE), Dermatophagoides species‐specific IgE (Der p‐sIgE), and component‐specific IgE (Der p1/2/10/23) were measured. IgE‐facilitated allergen binding (IgE‐FAB) assay evaluated blocking antibody activity.ResultsThe mean TNSS, CSMS, and MiniRQLQ scores were significantly reduced by 28.60% (p &lt; 0.001), 28.60% (p = 0.006), and 24.30% (p &lt; 0.001) respectively after 1 year of SCIT treatment. SCIT treatment significantly elevated serum tIgE and Der p sIgE levels (p &lt; 0.001), with a pronounced increase in component‐specific IgE positivity for Der p1 and Der p23 (p &lt; 0.001). The IgE‐FAB assay demonstrated that the average suppression of IgE‐allergen binding in serum by 1‐year SCIT was 4.48% (p &lt; 0.001).ConclusionSCIT markedly reduces subjective symptoms in patients with dust mite AR over a 1‐year treatment period. Component‐sIgE levels and IgE‐FAB inhibition could function as objective biomarkers for assessing immunotherapy efficacy, thus facilitating tailored clinical interventions.

The Clinical Efficacy and Safety of Endoscopic Vidian-Branch Neurectomy in Intractable Allergic Rhinitis.

Intractable allergic rhinitis (iAR) remains a clinical challenge. This study aims to evaluate the efficacy and safety of endoscopic selective vidian branch neurectomy for iAR. A prospective clinical study. A tertiary referral center. A total of 205 iAR patients were initially recruited and divided into 3 groups: endoscopic vidian-branch neurectomy (EVBN), endoscopic vidian neurectomy (EVN), and conservative treatment (control). All patients were followed up for more than 2 years, and the efficacy and postoperative complications were compared. After 2-year follow-up, a total of 195 patients were included, with 59 patients in EVBN group, 71 in EVN group, and 64 in control group. Post-treatment assessments at 6 months, 1 year, and 2 years revealed significant reductions in the total Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores and each domain in both EVBN and EVN groups compared to their baseline levels. However, no significant changes were observed in control group. Furthermore, the improvements in RQLQ 2 years post-treatment were higher in EVBN and EVN groups compared to control group. In EVBN group, only 3 (5.1%) patients reported mild eye dryness during the first month postoperation. However, in the EVN group, 15 (21.1%) patients experienced eye dryness, with 6 (8.5%) cases persisting for more than 1 year and remaining unresolved by the end of the 2-year follow-up. Both EVBN and EVN were effective in iAR patients. However, EVBN appears to be a safer option, associated with fewer postoperative complications.

Efficacy and safety of dupilumab in patients with moderate-to-severe atopic dermatitis and comorbid allergic rhinitis.

To examine the efficacy and safety of dupilumab treatment in moderate-to-severe atopic dermatitis (AD) patients with comorbid allergic rhinitis (AR). A total of 26 patients received subcutaneous dupilumab every 2 weeks and were followed up for 16 weeks. The efficacy assessment was evaluated based on clinical parameters every 4 weeks, including the Eczema Area and Severity Index (EASI), Pruritus Numeric Rating Scale (P-NRS), Severity Index (EASI), and Dermatology Life Quality Scale (DLQI) for the severity of AD symptoms, and the total nasal symptom scores (TNSS), visual analogue scale (VAS) and Mini Rhino-conjunctivitis Quality of Life Questionnaire (MiniRQLQ) for the severity of AR symptoms. The serum total immunoglobulin E (IgE) and eosinophil levels were collected at baseline and 16 weeks after dupilumab treatment. Treatment-emergent adverse events (TEAEs) ware conducted to evaluate the safety profile of dupilumab. Dupilumab treatment resulted in a significant improvement in AD symptoms after 16 weeks as demonstrated by reduced EASI, NRS, DLQI, and ADCT scores. In addition, dupilumab treatment had a significant improvement in AR symptoms based on reduced TNSS, VAS and MiniRQLQ scores. After 16 weeks of dupilumab treatment, the blood eosinophil count, eosinophil percentage, and total serum IgE levels were significantly decreased when compared with the baseline values (P < 0.01 both). During the treatment period, the incidence of TEAEs was 13.77% (n = 8). The most commonly reported TEAEs were injection-site reactions (n = 13, 60.25%). Dupilumab treatment resulted in clinically relevant improvements in symptoms of AD and AR and had an acceptable safety profile.

TAPAS-A Prospective, Multicentre, Long-Term Cohort Study in Children, Adolescents and Adults with Seasonal Allergic Rhinitis-Design and Early Results.

Background/Objectives: The guideline on allergen-specific immunotherapy of the European Academy of Allergy and Clinical Immunology recommends subcutaneous allergen-specific immunotherapy for the treatment of allergic rhinitis in children and adults with moderate to severe symptoms. The five years cohort study described below was designed in 2020 to demonstrate non-inferiority in terms of safety, tolerability and efficacy in a paediatric population compared with adult patients treated with microcrystalline tyrosine-adsorbed allergoids for their tree and grass pollen allergy in a perennial setting. Here, we present the preliminary findings from the first year. Methods: The Combined Symptom and Medication Score was chosen as the primary endpoint of this therapy. Secondary endpoints include the Rhinoconjunctivitis Quality of Life Questionnaire, the retrospective Rhinoconjunctivitis score, the Asthma Control Test and the Rhinitis Control Test, as well as an analysis of adverse drug reactions. Results: A total number of 320 patients were enrolled into this study, with 129 of these patients in the age group between 5 and 17 years and 191 patients in the adult age group. Mean Combined Symptom and Medication Score values did not differ significantly between minors and adults in the first pollen season after treatment induction. The retrospective score showed a strong and significant reduction in rhinoconjunctivitis and asthma symptoms. Treatment was well tolerated, with more than 80% of patients reporting no adverse drug reactions. Conclusions: The validity of this study approach of a cohort study has been confirmed by this first interim analysis for the initial course of therapy in the first year.

The nomogram prediction model for the risk of dropout in sublingual immunotherapy of patients with allergic rhinitis

Objective: To develop and externally validate a nomogram prediction model for assessing the risk of treatment dropout in allergic rhinitis (AR) patients undergoing sublingual immunotherapy (SLIT). Methods: Between February 2016 and December 2019, data from 358 and 259 AR patients undergoing SLIT were collected from Guizhou Provincial People's Hospital and Huangshi Central Hospital, respectively. The data included general patient information, dust mite sIgE levels, allergen types, and 22 other clinical variables. Data from Guizhou Provincial People's Hospital were used as the training set, while data from Huangshi Central Hospital were served as the external validation set. A multivariable Cox regression model was used to identify independent factors associated with SLIT dropout and to develop a nomogram prediction model. Results: Multivariate Cox regression analysis identified several significant factors influencing SLIT dropout, including dust mite sIgE levels (Grade Ⅱ-Ⅳ; HR=1.48, 95%CI: 1.16-1.88), presence of other allergic diseases (HR=0.47, 95%CI: 0.37-0.61), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score (HR=0.98, 95%CI: 0.97-1.00), WeChat management (HR=0.77, 95%CI: 0.60-0.98), treatment efficacy (HR=0.72, 95%CI: 0.56-0.92), age (5-17 years, HR=0.50, 95%CI: 0.36-0.71;≥60 years, HR=1.42, 95%CI: 1.08-1.87), household income (<5 000 CNY, HR=1.44, 95%CI: 1.09-1.90;>20 000 CNY, HR=0.66, 95%CI: 0.44-0.99), allergen types (single dust mite, HR=0.70, 95%CI: 0.49-0.93; and combined pollen or mold, HR=1.45, 95%CI: 1.02-2.04), and time to efficacy <3 months (HR=0.73, 95%CI: 0.56-0.94), all P<0.05. At the third-year follow-up, the area under curve (AUC) for the nomogram model was 0.913 (95%CI: 0.881-0.943) in the training group and 0.886 (95%CI: 0.838-0.933) in the validation group. Calibration and decision curve analyses demonstrated the model's consistency with actual dropout rates and clinical benefit in both groups. Additionally, a Brier score of 0.29 further confirmed the model's predictive accuracy. Conclusion: We successfully develop a nomogram-based prediction model for SLIT dropout in AR patients, which could assist healthcare professionals in effectively identifying high-risk patients and facilitate the development of more personalized and timely treatment plans aimed at enhancing patient compliance.

Improvement in symptom severity, asthma control, and quality of life in pediatric patients with seasonal allergic rhinitis

Objectives: To evaluate the allergic rhinitis (AR) symptoms, asthma control, and quality of life (QoL) outcomes following treatment in children with seasonal allergic rhinitis (SAR), with and without asthma. Methods: Children diagnosed with SAR and presenting during the pollen season were included in the study. Symptom severity of SAR was assessed using the Total Nasal Symptom Score (TNSS), Total Ocular Symptom Score (TOSS), and Visual Analog Scale (VAS). Asthma control was measured using the Childhood Asthma Control Test (C-ACT), Asthma Control Test (ACT), and CARATkids. Quality of life (QoL) was evaluated using the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire. Data were collected at admission, the first month, and the second month of treatment. Results: Fifty-five children aged 5-16 years with SAR were evaluated of whom twenty three (42%) had asthma. Sensitivities to grass, tree, and weed allergens were observed in 74.5%, 50.9%, and 80% of patients, respectively. During the study period, TNSS, TOSS, and VAS scores significantly decreased (P&amp;lt;0.05 for all). Significant improvements were also observed in CARATkids, C-ACT and ACT scores among SAR patients with asthma (P&amp;lt;0.05 for all). All domains of QoL score showed significant improvement (P&amp;lt;0.001 for all), and positively correlated with TNSS, TOSS, and VAS scores. In SAR patients with asthma, ACT and C-ACT scores demonstrated a positive correlation with QoL scores, while CARATkids scores showed a negative correlation. Conclusions: Treatment for SAR in children significantly reduces symptom severity, improves asthma control, and enhances QoL. Effective management of SAR is crucial for alleviating the disease burden and improving patients' overall well-being.

Nasal Nitric Oxide as an Objective Evaluation Tool for Treatment Response in Chronic Rhinitis

Background and ObjectivesInconsistencies in nasal nitric oxide (nNO) values, due to anatomical variations and comorbidities, challenge the accurate assessment of upper airway inflammation severity. We hypothesized that changes in nNO levels following treatment for chronic rhinitis would be consistent and provide relative value. This study aimed to evaluate the correlation between changes in nNO levels and symptomatic improvements following treatment for chronic rhinitis.Methods This prospective observational study included 46 participants diagnosed with chronic rhinitis between December 2021 and November 2023. nNO measurements, evaluations of four nasal and two ocular symptoms, and quality of life questionnaires were conducted at baseline and after one month of treatment. Baseline laboratory tests included serum total immunoglobulin E levels, blood eosinophil percentages, and skin prick tests.Results The Total Nasal Symptom Score (TNSS), TNSS with ocular symptoms (TNSS eye), and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores significantly decreased following treatment (all p<0.001). nNO levels also decreased significantly after treatment (p=0.036). Moreover, changes in nNO were significantly correlated with changes in TNSS, TNSS eye, and RQLQ scores (p=0.047, r=0.294; p=0.021, r=0.340; and p=0.004, r=0.419, respectively).Conclusion In patients with chronic rhinitis, changes in TNSS, TNSS eye, and RQLQ scores were correlated with changes in nNO levels after treatment. nNO may serve as a potential objective evaluation tool for chronic rhinitis, particularly in patients who have difficulty reporting symptoms.

Effectiveness of the Nasal Irrigation Effectiveness in Treating Allergic Rhinitis in Children 6 to 12 Years Old.

Nasal irrigation, a nonpharmacological intervention for alleviating nasal symptoms, has yet to gain widespread acceptance among caregivers due to procedural ambiguities and the absence of a standardized protocol. This study aimed to evaluate the efficacy of normal saline nasal irrigation in managing allergic rhinitis among children aged 6 to 12 years. This prospective, randomized, single-blind trial enrolled children aged 6 to 12 with allergic rhinitis. Patients were randomly assigned to receive either standard care (oral antihistamine and intranasal corticosteroid) or standard care plus nasal irrigation with saline solution. Symptom severity, assessed using the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) at baseline, 1, and 3 months, included rhinorrhea, nasal congestion, sneezing, pruritus, ocular symptoms, and functional impairment. The intervention group demonstrated statistically significant improvements in several domains post-intervention. Specifically, a marked reduction in sneezing frequency and nasal cleansing requirements was observed. Moreover, this group reported significantly lower ocular symptoms, including irritation, itching, and watering, relative to the control group. Although overall PRQLQ scores did not differ significantly between groups, the intervention group exhibited lower scores at the 1- and 3-month follow-ups, indicative of enhanced quality of life. These findings suggest a potential beneficial effect of the intervention on participant well-being. The findings of this study indicate that nasal irrigation with 0.65% saline solution 4 times daily may serve as an effective adjunct treatment for children with allergic rhinitis. This regimen was associated with significant enhancements in both nasal symptom severity and quality of life.

Ocular allergy and quality of life in a regional Australian optometry practice

ABSTRACT Clinical relevance Ocular allergy (OA) is likely to be a significant problem in regional Australia and may affect quality of life. Background Regional locations vary markedly in the types, quantities, and seasonality of allergens compared with urban environments. The aim of this research was to investigate the effects of OA on quality of life in patients presenting to a regional Australian optometric practice. Methods In this 12-month cross-sectional study, 107 adults with OA were recruited from a practice in Bundaberg, Australia. Self-reported symptoms, treatments, triggers and seasonality were recorded. Ocular itch was measured using the Numerical Rating Scale-11. Conjunctival hyperaemia and papillae were graded using the Efron Grading Scales. Tear meniscus height and non-invasive tear break-up time were measured using keratography. Participants completed the mini Rhino-Conjunctivitis Quality of Life Questionnaire (mini-RQLQ). Climate data for the month prior to presentation were collected. Results Mean age of participants was 56 years (SD 18 years) and 67% were female. Only 33.6% initially reported ocular itch. Papillae in the most affected eye was the only OA sign that correlated with overall mini-RQLQ score, although weakly (rho = 0.194, p = 0.046). Peak OA occurred mostly between July and January. Multiple regression analysis indicated correlations between overall mini-RQLQ score and OA history (p < 0.001) and worsening degree of OA symptoms in the past year (p = 0.002). Higher average minimum (p = 0.015) and higher average maximum temperatures (p = 0.008) in the month prior to presentation were associated with a worse mini-RQLQ ‘Eye Symptoms’ domain score. Conclusion Previous history of OA symptoms was significantly associated with worse quality of life. Optometrists should be aware of and consider the negative impact of OA on quality of life in developing management plans for patients with OA.

Efficacy and safety of sublingual immunotherapy using a combination of Dermatophagoides pteronyssinus and Blomia tropicalis extracts in patients with allergic rhinitis: A randomized, double-blind, placebo-controlled trial.

Efficacy and safety of sublingual immunotherapy using a combination of Dermatophagoides pteronyssinus and Blomia tropicalis extracts in patients with allergic rhinitis: A randomized, double-blind, placebo-controlled trial.

Montelukast sodium combined with levocabastine nasal spray demonstrates high efficacy in treating pediatric allergic rhinitis.

To investigate the efficacy and safety of montelukast sodium (MKS) combined with levocabastine (LEVO) nasal spray in treating pediatric allergic rhinitis and its impact on quality of life (AR). A total of 125 pediatric AR patients, diagnosed between September 2022 and September 2024, were enrolled and divided into two groups. The research group (n = 65) received MKS plus LEVO nasal spray, while the control group (n = 60) received LEVO nasal spray alone. Treatment efficacy, safety (assessing xerostomia, headache, and gastrointestinal disturbances), and clinical symptom scores (rhinorrhea, sneezing, nasal obstruction, and nasal pruritus) were evaluated. Additionally, nasal cavity parameters (nasal resistance (NR), minimum cross-sectional area (mCSA), and nasal cavity volume (NCV)), serum inflammatory markers (IL-4, IL-8, IL-10), serum biochemical indices (total immunoglobulin E [TlgE], eosinophil count [EOS], eosinophil cationic protein [ECP]), and quality of life (Rhinoconjunctivitis Quality of Life Questionnaire [RQLQ]) were analyzed. Univariate and multivariate binary logistic regression analyses were conducted to identify factors influencing treatment outcomes. The research group demonstrated significantly higher overall treatment efficacy than the control group (P<0.05), with a comparable safety profile (P>0.05). Post-treatment, clinical symptom scores, IL-4, IL-8, TlgE, EOS, ECP levels and RQLQ scores were significantly reduced in the research group compared to the control group (all P<0.05). Conversely, IL-10 levels were significantly higher in the research group (both P<0.05). Notably, passive secondhand smoke exposure, IL-10, EOS, and treatment modality were significantly associated with treatment efficacy (all P<0.05). Binary logistic regression identified passive secondhand smoke exposure (P = 0.035) and EOS (P = 0.036) as independent risk factors for treatment outcomes. The combination of MKS and LEVO nasal spray demonstrates superior efficacy and safety in pediatric AR treatment, significantly improving patients' quality of life. Moreover, treatment failure is closely linked to passive secondhand smoke exposure and elevated EOS levels.

Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial

Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis.

Acupuncture Point Embedding Therapy is a comprehensive treatment method that combines modern biomaterials with acupuncture techniques. Acupoint catgut embedding (ACE) not only avoids the adverse reactions associated with Western medicine but also incorporates the benefits of traditional acupuncture, extending the duration of its therapeutic effects. Allergic rhinitis (AR) is a condition known for its challenging treatment and tendency to persist. This randomized controlled trial included 128 AR patients to evaluate the effectiveness of ACE for AR management. Data were collected at baseline, four weeks after treatment, and eight weeks after treatment. Baseline analysis was performed, and the visual analog scale (VAS) was used as a clinical observation index for this method. The rhinoconjunctivitis quality of life questionnaire (RQLQ) served as a quality of life index. Specific IgE (sIgE), IL-4, IL-10, and IL-12 were used as laboratory observation indices. The results of the experiment validate the clinical effectiveness of ACE in treating AR. Although this technique is efficient and commonly used in clinics, its invasive nature poses risks of hospital-acquired infections. Based on this experiment, this protocol refines traditional techniques, providing detailed instructions on patient preparation, operation techniques, and postoperative care to ensure the safe and effective administration of therapy. By standardizing this therapy, ACE is anticipated to become an important non-drug treatment option for alleviating symptoms in AR patients, thereby significantly enhancing their quality of life.

Intranasal acupuncture therapy for allergic rhinitis: A systematic review and meta-analysis of randomized controlled trials.

Intranasal acupuncture therapy for allergic rhinitis: A systematic review and meta-analysis of randomized controlled trials.

Two types of vidian neurectomy show efficacy in treating allergic rhinitis and vasomotor rhinitis

This study aimed to evaluate the efficacies of endoscopic vidian neurectomy (VN) and highly selective vidian neurectomy (HSVN) for the treatment of allergic rhinitis (AR) and vasomotor rhinitis (VMR). All AR and VMR patients were divided into two groups, Group VN and Group HSVN. The efficacy evaluation methods were visual analog scale (VAS), rhinoconjunctivitis quality of life questionnaire (RQLQ), and medication score. The efficacy evaluations were used to assess patient rhinitis symptoms, quality of life and drug usage. The time points of follow-up period were preoperative, 3 months, 6 months, 1 year, 2 years, and 3 years post operation. By analyzing pre- and postoperative VAS, medication score and RQLQ score, the results showed that rhinitis symptoms and quality of life in both VN and HSVN groups were significantly improved at 3 years, and the rate of improvement decreased gradually with time. Post operation, there were no significant differences in VAS and medication scores between the VN and HSVN groups. With respect to RQLQ, postoperative 2 years and 3 years improvements in sleep disorders, non-nasal symptoms and eye symptoms were significantly greater in the HSVN group than in the VN group. Improvements in rhinitis symptoms and quality of life in AR and VMR were sustained by VN and HSVN until 3 years post operation, with greater quality of life improvements in the HSVN group.